Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN- Get a rating) received a consensus “Buy” recommendation from the eleven analysts who currently cover the company, reports MarketBeat.com. Two investment analysts rated the stock with a hold recommendation and eight gave the company a buy recommendation. The average 1-year price target among brokerages that have reported on the stock in the past year is $152.80.
Several equity analysts have recently released reports on BHVN shares. Mizuho raised its price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a Thursday, March 3 research report. HC Wainwright reiterated a “buy” rating and set a $160.00 price target on Biohaven Pharmaceutical shares in a Friday, January 7 research note. Morgan Stanley raised its price target on Biohaven Pharmaceutical from $145.00 to $148.00 and gave the stock an “equal weight” rating in a Friday, Jan. 7 research note. Finally, UBS Group raised its price target on Biohaven Pharmaceutical from $150.00 to $160.00 in a Tuesday, January 4 research note.
BHVN shares opened at $125.21 on Friday. The stock has a 50-day simple moving average of $125.89 and a 200-day simple moving average of $127.98. Biohaven Pharmaceutical has a 52 week low of $62.57 and a 52 week high of $151.51. The company has a market capitalization of $8.83 billion, a PE ratio of -9.57 and a beta of 1.08.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly earnings data on Thursday, February 24. The company reported ($3.01) earnings per share (EPS) for the quarter, missing Thomson Reuters consensus estimate of ($2.04) by ($0.97). The company posted revenue of $190.01 million in the quarter, versus analyst estimates of $175.54 million. During the same period of the previous year, the company achieved EPS ($3.62). The company’s revenue for the quarter increased by 441.1% compared to the same quarter last year. As a group, research analysts expect Biohaven Pharmaceutical to post EPS of -8.07 for the current fiscal year.
In other Biohaven Pharmaceutical news, Director Julia P. Gregory sold 12,000 shares of the company in a trade on Monday, December 20. The stock was sold at an average price of $125.00, for a total value of $1,500,000.00. The sale was disclosed in a document filed with the SEC, accessible via this link. Also, CAD George C. Clark sold 9,375 shares of the company in a trade on Wednesday, January 19. The shares were sold at an average price of $117.01, for a total value of $1,096,968.75. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 23,290 shares of the company worth $2,834,122. 15.20% of the shares are held by insiders of the company.
A number of hedge funds and other institutional investors have recently shifted their holdings to BHVN. Marshall Wace LLP acquired a new position in Biohaven Pharmaceutical in Q1 worth $365,000. Morgan Stanley increased its holdings of Biohaven Pharmaceutical shares by 30.6% during the 2nd quarter. Morgan Stanley now owns 53,669 shares of the company worth $5,210,000 after buying an additional 12,560 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings of Biohaven Pharmaceutical shares by 212.4% during Q2. Cubist Systematic Strategies LLC now owns 9,727 shares of the company worth $944,000 after purchasing an additional 6,613 shares last quarter. Prudential Financial Inc. increased its holdings of Biohaven Pharmaceutical shares by 8.4% during the second quarter. Prudential Financial Inc. now owns 4,496 shares of the company worth $437,000 after buying 350 additional shares in the last quarter. Finally, Man Group plc acquired a new equity stake in Biohaven Pharmaceutical during Q2 worth $521,000. 91.73% of the shares are currently held by hedge funds and other institutional investors.
Biohaven Pharmaceutical Company Profile (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here